An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MRG003 in Combination With HX008 in Patients With EGFR-positive Advanced Solid Tumors
Latest Information Update: 09 Jul 2024
At a glance
- Drugs MRG 003 (Primary) ; Pucotenlimab (Primary)
- Indications Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Miracogen
- 04 Jun 2024 Preliminary results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 20 Jan 2023 New trial record